Logo

Fierce Biotech

 http://www.fiercebiotech.com/

  • By Fierce Biotech   -   Apr 13, 2021

    AACR: ONCOMYX'S ENGINEERED RABBIT POX VIRUS SHOWS PROMISE IN LUNG CANCER MODEL

    AACR: OncoMyx's engineered rabbit pox virus shows promise in lung cancer model aliu Sun, 04/11/2021 - 11:39

    Virus, Cancer, Engineering
  • By Fierce Biotech   -   Apr 13, 2021

    SANOFI PAYS $160M FOR MRNA TECH TO REPROGRAM T CELLS IN VIVO

    Sanofi pays $160M for mRNA tech to reprogram T cells in vivo ntaylor Mon, 04/12/2021 - 05:45

  • By Fierce Biotech   -   Apr 13, 2021

    VACCITECH, THE COMPANY THAT DEVELOPED THE ASTRAZENECA COVID-19 SHOT, FILES FOR A NASDAQ IPO

    Vaccitech, the company that developed the AstraZeneca COVID-19 shot, files for a Nasdaq IPO badams Mon, 04/12/2021 - 07:32

    NASDAQ
  • By Fierce Biotech   -   Apr 13, 2021

    AACR: MD ANDERSON TEAM UNCOVERS NEW TARGET FOR BLOCKING MUTANT KRAS AND P53 IN PANCREATIC CANCER

    AACR: MD Anderson team uncovers new target for blocking mutant KRAS and p53 in pancreatic cancer arlene.weintraub Mon, 04/12/2021 -...

    Cancer
  • By Fierce Biotech   -   Apr 13, 2021

    SAGE, BIOGEN'S TREMOR DRUG HITS GOAL, BUT 38% OF PEOPLE DROP OUT 

    Sage, Biogen's tremor drug hits goal, but 38% of people drop out ntaylor Mon, 04/12/2021 - 08:23

    Drugs, Drug
  • By Fierce Biotech   -   Apr 13, 2021

    COVID PLAYER AND PFIZER-PARTNERED VALNEVA EYES $100M NASDAQ IPO

    COVID player and Pfizer-partnered Valneva eyes $100M Nasdaq IPO badams Mon, 04/12/2021 - 10:25

    NASDAQ
  • By Fierce Biotech   -   Apr 13, 2021

    MIT AND UCSF RESEARCHERS CREATE CRISPR ‘ON-OFF SWITCH' THAT CONTROLS GENE EXPRESSION WITHOUT CHANGING DNA

    MIT and UCSF researchers create CRISPR ‘on-off switch' that controls gene expression without changing DNA arlene.weintraub Thu, 04/08/2021...

    Research, Genes, DNA, Gene
  • By Fierce Biotech   -   Apr 13, 2021

    WEREWOLF THERAPEUTICS LOOKS TO MAKE A KILLING IN THE PUBLIC MARKETS WITH A $100M IPO

    Werewolf Therapeutics looks to make a killing in the public markets with a $100M IPO badams Fri, 04/09/2021 - 03:26

    Therapeutics
  • By Fierce Biotech   -   Apr 13, 2021

    PROVENTION WARNS FDA REQUESTS COULD DELAY DIABETES APPROVAL

    Provention warns FDA requests could delay diabetes approval ntaylor Fri, 04/09/2021 - 05:51

  • By Fierce Biotech   -   Apr 13, 2021

    SANOFI DROPS 'INTRIGUING' DATA ON RIVAL TO BRISTOL MYERS' BEMPEG

    Sanofi drops 'intriguing' data on rival to Bristol Myers' bempeg ntaylor Fri, 04/09/2021 - 05:57

  • By Fierce Biotech   -   Apr 13, 2021

    CHUTES & LADDERS-3 WEEKS AFTER LEAVING BLUEBIRD, CMO DAVIDSON LANDS AT TESSERA

    Chutes & Ladders-3 weeks after leaving bluebird, CMO Davidson lands at Tessera fkansteiner Fri, 04/09/2021 - 07:29

  • By Fierce Biotech   -   Apr 13, 2021

    LIFE SCIENCES PUMPING MORE CASH THAN EVER INTO R&D, BUT DRUG PRICING LIMITS COULD STYMIE THAT TIDE: REPORT

    Life sciences pumping more cash than ever into R&D, but drug pricing limits could stymie that tide: report badams Fri, 04/09/2021 -...

    Drugs, Life Sciences, Drug, R&D, Science
  • By Fierce Biotech   -   Apr 13, 2021

    VENTUS RAISES $100M TO PURSUE NLRP3, CRACK UNDRUGGABLE TARGETS

    Ventus raises $100M to pursue NLRP3, crack undruggable targets ntaylor Thu, 04/08/2021 - 02:13

  • By Fierce Biotech   -   Apr 13, 2021

    CYTODYN'S CHIEF SCIENTIFIC OFFICER RAHMAN QUIETLY EXITS AMID LERONLIMAB LIMBO

    CytoDyn's chief scientific officer Rahman quietly exits amid leronlimab limbo badams Thu, 04/08/2021 - 04:40

  • By Fierce Biotech   -   Apr 13, 2021

    LILLY, ABCELLERA TOUT COVID-19 ANTIBODY COMBO POTENTIAL AS IT LOSES STRENGTH AGAINST VARIANTS

    Lilly, AbCellera tout COVID-19 antibody combo potential as it loses strength against variants aliu Thu, 04/08/2021 - 06:13

  • By Fierce Biotech   -   Apr 13, 2021

    BANNISTER JOINS SVB TO HELP COMPANIES RAISE CASH, ACCESS PUBLIC MARKETS

    Bannister joins SVB to help companies raise cash, access public markets ntaylor Thu, 04/08/2021 - 08:17

  • By Fierce Biotech   -   Apr 13, 2021

    ICOSAVAX RAISES $100M TO TAKE RSV, COVID-19 VACCINES INTO CLINIC

    Icosavax raises $100M to take RSV, COVID-19 vaccines into clinic ntaylor Wed, 04/07/2021 - 08:22

    Vaccine, Vaccines, Clinical
  • By Fierce Biotech   -   Apr 13, 2021

    BAYER-BACKED METAGENOMI BUMPS UP SERIES A TO $75M AS IT GEARS UP FOR GENE EDITING PUSH

    Bayer-backed Metagenomi bumps up series A to $75M as it gears up for gene editing push badams Wed, 04/07/2021 - 09:07

    Genes, Gene
  • By Fierce Biotech   -   Apr 13, 2021

    BLUEBIRD'S CHIEF MEDICAL OFFICER FLIES THE NEST TO GENE WRITING BIOTECH TESSERA

    Bluebird's chief medical officer flies the nest to gene writing biotech Tessera badams Wed, 04/07/2021 - 07:05

    Biotech, Genes, BioTech, Gene
  • By Fierce Biotech   -   Apr 13, 2021

    NOVARTIS TAPS ARTIOS FOR TARGETS TO ENHANCE RADIOLIGAND DRUGS

    Novartis taps Artios for targets to enhance radioligand drugs ntaylor Tue, 04/06/2021 - 12:02

    Drugs, Drug

Next